Molecular mechanism of ATF6 in unfolded protein response and its role in disease.

Activating transcription factor 6 (ATF6) Endoplasmic reticulum stress (ERS) Proteostasis Unfolded protein response (UPR)

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 01 11 2023
revised: 04 02 2024
accepted: 05 02 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

Activating transcription factor 6 (ATF6), an important signaling molecule in unfolded protein response (UPR), plays a role in the pathogenesis of several diseases, including diseases such as congenital retinal disease, liver fibrosis and ankylosing spondylitis. After endoplasmic reticulum stress (ERS), ATF6 is activated after separation from binding immunoglobulin protein (GRP78/BiP) in the endoplasmic reticulum (ER) and transported to the Golgi apparatus to be hydrolyzed by site 1 and site 2 proteases into ATF6 fragments, which localize to the nucleus and regulate the transcription and expression of ERS-related genes. In these diseases, ERS leads to the activation of UPR, which ultimately lead to the occurrence and development of diseases by regulating the physiological state of cells through the ATF6 signaling pathway. Here, we discuss the evidence for the pathogenic importance of ATF6 signaling in different diseases and discuss preclinical results.

Identifiants

pubmed: 38434326
doi: 10.1016/j.heliyon.2024.e25937
pii: S2405-8440(24)01968-6
pmc: PMC10907738
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e25937

Informations de copyright

© 2024 Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yingying Lei (Y)

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.

Hong Yu (H)

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.

Shaoxue Ding (S)

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.

Hui Liu (H)

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.

Chunyan Liu (C)

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.

Rong Fu (R)

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.

Classifications MeSH